| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S81068-10mg |
99.9% | ￥500.00 | >10 | - | - | - |
|
S81068-100mg |
99.9% | ￥1900.00 | 9 | - | - | - |
|
Manidipine, a calcium channel blocker, which is dihydropyridine type. It is utilized
| 產(chǎn)品描述： | Manidipine, a calcium channel blocker, which is dihydropyridine type. It is utilized | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Calcium Channel;CalciumChannel | ||||||||||||||||||||
| 體內(nèi)研究： | Manidipine reduces systolic blood pressure with a slight sympathetic reflex increase in heart rate, and increases plasma nitrite/nitrates in perfused rat heart from ischemia-reperfusion damage. Manidipine combined with Simvastatin reduces creatine kinase, lactate dehydrogenase and tumor necrosis factor-alpha, and enhancement of 6-keto-PGF(1alpha) during reperfusion. Manidipine hydrochloride prevents isoproterenol-induced left ventricular hypertrophy and expression of mRNA of ANP, collagen types I and type III, and fibronectin in rats with isoproterenol-induced cardiac hypertrophy. Manidipine HCl increases renal blood flow (RBF) by dilating the afferent arterioles and improves glomerular hypertension by dilating the efferent arterioles in hypertensive rats. | ||||||||||||||||||||
| 參考文獻： | 1.Yoshiyama M, et al. Jpn Circ J, 1998, 62(1), 47-52. 2.Rossoni G, et al. Eur J Pharmacol, 2008, 587(1-3), 224-230. 3.Roth M, et al. Proc Natl Acad Sci U S A, 1992, 89(9), 4071-4075. 4.Tojo A, et al. J Cardiovasc Pharmacol, 1992, 20(6), 895-899. 5.Huang S, et al. Am Heart J, 1993, 125(2 Pt 2), 589-597. | ||||||||||||||||||||
| 溶解性： | DMSO:113 mg/mL (185 mM) H2O:<1 mg/mL Ethanol:3 mg/mL (4.91 mM) | ||||||||||||||||||||
| 保存條件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京